Evidence map›Paper›PMID 28067870›Full record

ArticleBone marrow transplantation2017

A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation.

B M Haverkos, Y Huang, P Elder, L O'Donnell, D Scholl, B Whittaker, S Vasu, S Penza, L A Andritsos, S M Devine and 1 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03244930 (Low Dose Plerixafor Plus G-CSF Efficiency in Mobilizing Stem Cells From Lymphoma and Myeloma Patients for Autologous Peripheral Blood Transplantation), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03244930 phase2unknown statusnot on this map

Low Dose Plerixafor Plus G-CSF Efficiency in Mobilizing Stem Cells From Lymphoma and Myeloma Patients for Autologous Peripheral Blood Transplantation

TypeinterventionalSponsorHospital Universitario Dr. Jose E. GonzalezRan2017 to 2018Enrolled20ConditionsLymphoma, Non-Hodgkin, Lymphoma, Hodgkin, Myeloma, Stem Cell Transplant ComplicationsArmsPlerixafor 0.12 mg/kg
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

B M HaverkosDivision of Hematology, University of Colorado, Aurora, CO, USA.
Y HuangDivision of Hematology, The Ohio State University, Columbus, OH, USA.
P ElderDivision of Hematology, The Ohio State University, Columbus, OH, USA.
L O'DonnellDivision of Hematology, The Ohio State University, Columbus, OH, USA.
D SchollDivision of Hematology, The Ohio State University, Columbus, OH, USA.
B WhittakerDivision of Hematology, The Ohio State University, Columbus, OH, USA.
S VasuDivision of Hematology, The Ohio State University, Columbus, OH, USA.
S PenzaDivision of Hematology, The Ohio State University, Columbus, OH, USA.
L A AndritsosDivision of Hematology, The Ohio State University, Columbus, OH, USA.
S M DevineDivision of Hematology, The Ohio State University, Columbus, OH, USA.
S M JaglowskiDivision of Hematology, The Ohio State University, Columbus, OH, USA.

Funding

Training Hematology and Oncology Fellows in Clinical ResearchT32CA165998 · NCI · OHIO STATE UNIVERSITY · PI CLINTON, STEVEN K, GARZON, RAMIRO · 2012 to 2016
$944k
NCI NIH HHS L30 CA189070NCI NIH HHS T32 CA165998
6 · The paper itself

Abstract

In an otherwise eligible patient with relapsed lymphoma, inadequate mobilization of hematopoietic stem cells (HSCs) is a limiting factor to proceeding with an autologous hematopoietic cell transplantation (auto-HCT). Multiple strategies have been used to mobilize an adequate number of HSCs with no obvious front-line strategy. We report a single institutional experience mobilizing HSCs using four different approaches in lymphoma patients. We prospectively collected mobilization outcomes on patients planned to undergo auto-HCT at Ohio State University. We report results of first mobilization attempts for all relapsed or refractory lymphoma patients between 2008 and 2014. We identified 255 lymphoma patients who underwent mobilization for planned auto-HCT. The 255 lymphoma patients underwent the following front line mobilization strategies: 95 (37%) G-CSF alone, 38 (15%) chemomobilization (G-CSF+chemotherapy), 97 (38%) preemptive day 4 plerixafor, and 25 (10%) rescue day 5 plerixafor. As expected, there were significant differences between cohorts including age, comorbidity indices, histology, and amount of prior chemotherapy. After controlling for differences between groups, the odds of collecting 2 × 10

Indexed as

AdultAgedAntigens, CD34Antineoplastic AgentsBenzylaminesCell CountCyclamsFemaleGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHematopoietic Stem CellsHematopoietic Stem Cell TransplantationHeterocyclic CompoundsHumansLymphomaMaleAntigens, CD34Antineoplastic AgentsBenzylaminesCyclamsGranulocyte Colony-Stimulating FactorHeterocyclic Compoundsplerixafor

Identifiers

PMID28067870
PMCPMC5382040

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.